# Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

> **NCT06138613** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 705 (actual)

## Conditions studied

- Motion Sickness

## Interventions

- **DRUG:** Tradipitant

## Key facts

- **NCT ID:** NCT06138613
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-27
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 705 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138613, "Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06138613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*